Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 925 of 942 entries
View as:
Phase: N/A
Priority: Normal
Start: 08/01/25
End: 08/01/27
Due: 08/01/28
Phase: N/A
Priority: Normal
Start: 04/30/06
End: 11/30/14
Due: 11/30/15
Phase: N/A
Priority: Normal
Start: 01/13/21
End: 06/14/24
Due: 06/14/25
Phase: N/A
Priority: Normal
Start: 09/30/03
End: 02/28/11
Due: 02/28/12
Phase: N/A
Priority: Normal
Start: -
End: -
Due: -
Phase: N/A
Priority: Normal
Start: 07/31/09
End: 05/31/12
Due: 05/31/13
Phase: N/A
Priority: Normal
Start: 08/31/22
End: 09/30/23
Due: 09/30/24
Phase: N/A
Priority: Normal
Start: 05/01/23
End: 05/01/26
Due: 05/01/27
Phase: N/A
Priority: Normal
Start: 11/15/25
End: 12/01/31
Due: 12/01/32
Phase: N/A
Priority: Normal
Start: 03/31/11
End: 11/30/12
Due: 11/30/13
Phase: N/A
Priority: Normal
Start: 06/26/18
End: 11/22/24
Due: 11/22/25
Phase: N/A
Priority: Normal
Start: 05/31/16
End: 09/30/17
Due: 09/30/18
Phase: N/A
Priority: Normal
Start: 05/31/08
End: 01/20/11
Due: 01/20/12
Phase: N/A
Priority: Normal
Start: 08/19/19
End: 02/13/23
Due: 02/13/24
Phase: N/A
Priority: Normal
Start: 01/31/17
End: 10/13/20
Due: 10/13/21
Phase: N/A
Priority: Normal
Start: 12/26/23
End: 12/31/34
Due: 12/31/35
Phase: N/A
Priority: Normal
Start: 11/30/15
End: 06/30/20
Due: 06/30/21
Phase: N/A
Priority: Normal
Start: 11/30/12
End: 11/30/17
Due: 11/30/18
Phase: N/A
Priority: Normal
Start: 04/01/25
End: 10/31/28
Due: 10/31/29
Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer
Phase: N/A
Priority: Normal
Start: 06/25/12
End: 06/05/17
Due: 06/05/18
Phase: N/A
Priority: Normal
Start: 07/17/15
End: 08/20/24
Due: 08/20/25
Phase: N/A
Priority: Normal
Start: 04/30/16
End: 02/28/18
Due: 02/28/19
Phase: N/A
Priority: Normal
Start: 03/24/11
End: 11/09/15
Due: 11/09/16
Phase: N/A
Priority: Normal
Start: 11/30/13
End: 12/31/18
Due: 12/31/19
Phase: N/A
Priority: Normal
Start: 10/30/20
End: 12/14/22
Due: 12/14/23